JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Neal Flomenberg, the Chief Scientific Officer and Global R&D Lead at Tevogen Bio Holdings Inc. (NASDAQ:TVGN), has sold a significant portion of his holdings in the company. According to a recent SEC filing, Flomenberg sold 232,968 shares of common stock at a weighted average price of $1.09 per share, totaling approximately $253,935. The transactions occurred on March 12, 2025, and were primarily conducted to cover tax obligations related to the vesting and settlement of restricted stock units. Following these sales, Flomenberg retains ownership of 3,595,608 shares in the company. InvestingPro analysis indicates the company’s financial health score is currently rated as WEAK, with short-term obligations exceeding liquid assets. Subscribers can access 8 additional ProTips and comprehensive financial metrics for deeper insight into TVGN’s performance and outlook.
In other recent news, Tevogen Bio has filed for a new patent with the U.S. Patent and Trademark Office for its T cell vaccine technology. This innovative approach aims to stimulate a T cell response to the entire viral genome, addressing challenges posed by viral mutations. The company has reported positive safety data from its clinical trial and holds several granted and pending patents. In other developments, Tevogen Bio received a Buy rating from Boral (OTC:BOALY) Capital, which set a price target at $10.00, highlighting optimism about the company’s T cell immunotherapies. The firm’s lead product, TVGN-489, is under development to aid high-risk COVID-19 patients, including those with cancer. Additionally, Tevogen Bio announced an expanded collaboration with Microsoft (NASDAQ:MSFT) to enhance its AI-driven PredicTcell technology. This partnership aims to leverage Microsoft’s AI and cloud capabilities for predictive precision T-cell targeting. These developments reflect Tevogen Bio’s continued efforts in advancing its clinical programs and technological innovations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.